Curreen Capital breaks down Fortrea’s struggles and turnaround potential. Learn why this CRO stock might rebound and what it means for long-term investors.

SkyQuest Technology Consulting published a report, titled, Biomarkers Market - Global Opportunity Analysis and Industry ...

Revenue (GAAP) missed expectations, falling to $156.8 million in Q2 2025—down approximately 14% from the prior year quarter and 5.4% below analyst estimates. GAAP net loss deepened to $0.19 per share, ...

Dr Mary Talley Bowden was temporarily locked out of her X account for helping followers find resources from LabCorp.

Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond ...

First-and-only test of its kind approved under new European Union regulations expands access to personalized cancer care for patients across the EU BURLINGTON, N.C.

Investment management company Curreen Capital released its second-quarter 2025 Investor letter. A copy of the letter can be ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today PGDx elio™ tissue complete has been CE-marked under the European Union's (EU) new In Vitro ...

The US Food and Drug Administration (FDA) has approved an improved stool collection kit of Geneoscopy’s CRC screening test, ColoSense.

Detailed price information for Laboratory Corp of America Holdings (LH-N) from The Globe and Mail including charting and trades.

We primarily deployed the proceeds from selling Nilorn into Havas in the first quarter and into Fortrea during the second quarter.